BioLineRx Stock Soars 46% On Positive Phase 2 Pancreatic Cancer Trial Data

(RTTNews) - BioLineRx Ltd. (BLRX) shares surged 45.88 percent to $5.66, up $1.83 on Friday, after announcing that new data from its Phase 2 CheMo4METPANC clinical trial will be presented at the 2025 ASCO Annual Meeting. BioLineRx is currently trading at $7.11, compared to a previous close of $3.88 on the Nasdaq. The stock opened at $5.80 and has ranged between $5.25 and $7.77 on the day, with trading volume exceeding 26.5 million shares. Its 52-week range is $2.30 to $35.60.

The trial evaluates BioLineRx's CXCR4 inhibitor motixafortide in combination with the PD-1 inhibitor cemiplimab and standard chemotherapies for first-line treatment of pancreatic cancer. Updated results from the pilot phase showed that four of eleven patients remained progression-free for over a year.